...
首页> 外文期刊>Current medical research and opinion >Comparison of safety outcomes among Caucasian, Hispanic, Black, and Asian patients in duloxetine studies of chronic painful conditions
【24h】

Comparison of safety outcomes among Caucasian, Hispanic, Black, and Asian patients in duloxetine studies of chronic painful conditions

机译:在度洛西汀研究慢性疼痛情况下,白种人,西班牙裔,黑人和亚裔患者的安全性结果比较

获取原文
获取原文并翻译 | 示例

摘要

Objective: This post-hoc analysis was conducted to investigate if safety outcomes differed among race/ethnic subgroups of patients treated with duloxetine for chronic painful conditions. Research design and methods: Pooled data from 15 placebo-controlled clinical trials were used to compare the safety outcomes of duloxetine among patients of Caucasian, Hispanic, Asian, and Black race/ethnic origins. Patients were randomized to receive placebo (n=2199) or duloxetine (n=3148) for treatment of diabetic peripheral neuropathic pain, fibromyalgia, osteoarthritis pain, or chronic low back pain. For categorical outcomes such as study discontinuation, adverse events leading to discontinuation, and treatment-emergent adverse events, incidence rates were summarized by race/ethnic subgroups. The Breslow-Day test was used to assess the homogeneity of treatment odds ratios across the four subgroups. For continuous outcomes such as changes in vital signs, body weight, and laboratory measures, an analysis of covariance or analysis of variance model was used and duloxetine effects were compared among race/ethnic subgroups based on the test of treatment-by-subgroup interaction. Results: No significant differences were found among race/ethnic subgroups for discontinuation due to adverse events except for anxiety (p=0.040). Rates of nausea and decreased appetite were significantly higher (p≤0.05) in duloxetine-treated patients compared with placebo-treated patients within each race/ethnic subgroup. The Breslow-Day test was not significant for most safety outcomes, nor were treatment-by-race/ethnic subgroup interactions (p>0.1), which suggested duloxetine effects were not significantly different among race/ethnic subgroups. Conclusion: Overall, these results detected only minimal differences among safety outcomes assessed in these race/ethnic subgroups in patients treated with duloxetine for chronic painful conditions. The unbalanced sample sizes among the race/ethnic subgroups may have limited the power to detect treatment by race subgroup interactions. These post-hoc subgroup analyses were of an exploratory nature and the results should be interpreted with appropriate caution.
机译:目的:本事后分析旨在调查在长期疼痛情况下接受度洛西汀治疗的患者的种族/族裔亚组之间的安全性结果是否存在差异。研究设计和方法:来自15个安慰剂对照临床试验的汇总数据用于比较度洛西汀在白种人,西班牙裔,亚裔和黑人种族/族裔患者中的安全性结果。患者被随机分配接受安慰剂(n = 2199)或度洛西汀(n = 3148)治疗糖尿病周围神经性疼痛,纤维肌痛,骨关节炎疼痛或慢性下腰痛。对于分类结果,例如研究中止,导致中止的不良事件和治疗紧急不良事件,按种族/族裔亚组总结了发病率。 Breslow-Day检验用于评估四个亚组中治疗几率的均一性。对于生命体征,体重变化和实验室指标变化等连续结果,使用协方差分析或方差分析模型,并根据逐组治疗的交互作用比较种族/族裔亚组的度洛西汀效果。结果:除焦虑外,种族/族裔亚组间因不良事件而终止治疗的差异无统计学意义(p = 0.040)。与每个种族/族裔亚组中的安慰剂治疗患者相比,度洛西汀治疗的患者恶心和食欲下降的比率显着更高(p≤0.05)。 Breslow-Day检验对大多数安全性结果均无显着意义,种族/种族间的相互作用也不显着(p> 0.1),这表明度洛西汀的作用在种族/种族间无显着差异。结论:总的来说,在用度洛西汀治疗慢性疼痛的患者中,这些结果仅检测到在这些种族/族裔亚组中评估的安全性结果之间的最小差异。种族/族裔亚组之间样本量的不平衡可能限制了通过种族亚组相互作用检测治疗的能力。这些事后的亚组分析具有探索性,应谨慎解释结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号